AR060448A1 - Inhibicion mediada por rnai de afecciones inflamatorias relacionadas con tirosina quinasa del bazo - Google Patents
Inhibicion mediada por rnai de afecciones inflamatorias relacionadas con tirosina quinasa del bazoInfo
- Publication number
- AR060448A1 AR060448A1 ARP070101581A ARP070101581A AR060448A1 AR 060448 A1 AR060448 A1 AR 060448A1 AR P070101581 A ARP070101581 A AR P070101581A AR P070101581 A ARP070101581 A AR P070101581A AR 060448 A1 AR060448 A1 AR 060448A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- nucleotides
- syk
- region
- mrna
- Prior art date
Links
- 230000005764 inhibitory process Effects 0.000 title abstract 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 title 1
- 108091030071 RNAI Proteins 0.000 title 1
- 230000002757 inflammatory effect Effects 0.000 title 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 title 1
- 239000002773 nucleotide Substances 0.000 abstract 7
- 125000003729 nucleotide group Chemical group 0.000 abstract 7
- 108020004999 messenger RNA Proteins 0.000 abstract 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract 3
- 230000004968 inflammatory condition Effects 0.000 abstract 2
- 206010010744 Conjunctivitis allergic Diseases 0.000 abstract 1
- 201000004624 Dermatitis Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000035268 Mast Cell Activation disease Diseases 0.000 abstract 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 abstract 1
- 102000000551 Syk Kinase Human genes 0.000 abstract 1
- 108010016672 Syk Kinase Proteins 0.000 abstract 1
- 229940112258 acular Drugs 0.000 abstract 1
- 208000002205 allergic conjunctivitis Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 208000024998 atopic conjunctivitis Diseases 0.000 abstract 1
- 230000002238 attenuated effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000009368 gene silencing by RNA Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000002452 interceptive effect Effects 0.000 abstract 1
- BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 206010039083 rhinitis Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79184706P | 2006-04-13 | 2006-04-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR060448A1 true AR060448A1 (es) | 2008-06-18 |
Family
ID=38610402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070101581A AR060448A1 (es) | 2006-04-13 | 2007-04-13 | Inhibicion mediada por rnai de afecciones inflamatorias relacionadas con tirosina quinasa del bazo |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US8048863B2 (cg-RX-API-DMAC7.html) |
| EP (3) | EP2662446A3 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2009533475A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20080110900A (cg-RX-API-DMAC7.html) |
| CN (2) | CN101443020A (cg-RX-API-DMAC7.html) |
| AR (1) | AR060448A1 (cg-RX-API-DMAC7.html) |
| AU (2) | AU2007238027B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0709506A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2649138C (cg-RX-API-DMAC7.html) |
| MX (2) | MX2008013068A (cg-RX-API-DMAC7.html) |
| TW (2) | TW201336514A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2007121347A2 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200808744B (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009046059A1 (en) * | 2007-10-01 | 2009-04-09 | Alcon Research, Ltd. | Self complementary aav-mediated delivery of interfering rna molecules to treat or prevent ocular disorders |
| US20110123637A1 (en) * | 2008-05-26 | 2011-05-26 | Universitat Zurich | Protamine/rna nanoparticles for immunostimulation |
| WO2010074992A2 (en) * | 2008-12-22 | 2010-07-01 | Otonomy, Inc. | Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders |
| EP2865758A1 (en) * | 2013-10-22 | 2015-04-29 | Sylentis, S.A.U. | siRNA and their use in methods and compositions for inhibiting the expression of the ORAI1 gene |
| CN104805085A (zh) * | 2014-01-29 | 2015-07-29 | 江苏命码生物科技有限公司 | 串联表达的siRNA及其在治疗慢性淋巴细胞白血病中的应用 |
| MX383367B (es) * | 2014-12-29 | 2025-03-13 | Toray Ind Inc Star | Composición que contiene establemente una molécula de ácido nucleico. |
| WO2016192741A1 (en) | 2015-05-29 | 2016-12-08 | Ablacon Inc. | Elongated medical device suitable for intravascular insertion, optical force sensing assembly for an elongated medical device and method of making a medical optical force sensing assembly |
| MX2018005146A (es) * | 2015-10-30 | 2018-08-23 | Bonac Corp | Composicion que contiene de manera estable molecula de acido nucleico de un solo filamento que suprime la expresion de gen tgf-b1. |
| BR102018001541B1 (pt) | 2018-01-24 | 2021-05-11 | Universidade Federal Do Rio Grande Do Sul | composição farmacêutica nanométrica na forma de lipossomas ou nanoemulsão que contém sequências específicas de rna de interferência |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5360720A (en) | 1993-10-08 | 1994-11-01 | Alcon Laboratories, Inc. | Method of preparing human conjunctival mast cells for mast cell stabilization assays |
| US5545626A (en) * | 1994-01-19 | 1996-08-13 | The Trustees Of Columbia University In The City Of New York | Method of treating glaucoma with oligonucleotides |
| EP0831875A4 (en) * | 1995-06-07 | 2002-07-31 | Univ Pennsylvania | METHODS OF INHIBITING PHAGOCYTOSIS |
| AU2004266311B2 (en) * | 2001-05-18 | 2009-07-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| US20050227935A1 (en) * | 2001-05-18 | 2005-10-13 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of TNF and TNF receptor gene expression using short interfering nucleic acid (siNA) |
| EP2157191B1 (en) * | 2002-10-01 | 2013-12-25 | Epigenomics AG | Use of PITX2 nucleic acids for the improved treatment of breast cell proliferative disorders |
| WO2006006948A2 (en) | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
| US8090542B2 (en) * | 2002-11-14 | 2012-01-03 | Dharmacon Inc. | Functional and hyperfunctional siRNA |
| CN1742086B (zh) * | 2002-11-22 | 2010-05-12 | 生物智囊团株式会社 | Rna干扰的目标碱基序列的搜索方法 |
| AU2003224132A1 (en) * | 2003-04-24 | 2004-11-19 | Galapagos Genomics N.V. | Effective sirna knock-down constructs |
| JP2007524397A (ja) * | 2003-07-03 | 2007-08-30 | ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア | Ｓｙｋキナーゼ発現の阻害 |
| CA2546067A1 (en) * | 2003-11-14 | 2005-06-02 | Yale University | Fcyriia-specific nucleic acid interference |
| GB0404209D0 (en) | 2004-02-25 | 2004-03-31 | Uws Ventures Ltd | Materials and methods for treatment of allergic disease |
| US20060058255A1 (en) * | 2004-03-01 | 2006-03-16 | Jianzhu Chen | RNAi-based therapeutics for allergic rhinitis and asthma |
| US20090005268A1 (en) * | 2005-07-18 | 2009-01-01 | Epigenomics Ag | Compositions and Methods for Cancer Diagnostics Comprising Pan-Cancer Markers |
| JP5400388B2 (ja) * | 2005-12-15 | 2014-01-29 | ライジェル ファーマシューティカルズ， インコーポレイテッド | キナーゼインヒビターおよびその利用 |
| CL2008002277A1 (es) | 2007-08-03 | 2009-07-17 | Alcon Res Ltd | Metodo para tratar un trastorno ocular relacionado con tnf alfa que comprende una molecula de arn interferente que actua en la expresion del arnm de tnfr1 o tace mediante interferencia de arn; molecula de arn interferente; composicion que comprende dicho interferente. |
-
2007
- 2007-04-12 TW TW102118618A patent/TW201336514A/zh unknown
- 2007-04-12 TW TW096112900A patent/TW200808360A/zh unknown
- 2007-04-13 EP EP20130176714 patent/EP2662446A3/en not_active Withdrawn
- 2007-04-13 KR KR1020087027710A patent/KR20080110900A/ko not_active Ceased
- 2007-04-13 AR ARP070101581A patent/AR060448A1/es unknown
- 2007-04-13 CN CNA2007800131881A patent/CN101443020A/zh active Pending
- 2007-04-13 BR BRPI0709506-6A patent/BRPI0709506A2/pt not_active IP Right Cessation
- 2007-04-13 AU AU2007238027A patent/AU2007238027B2/en not_active Ceased
- 2007-04-13 JP JP2009505636A patent/JP2009533475A/ja active Pending
- 2007-04-13 CA CA2649138A patent/CA2649138C/en active Active
- 2007-04-13 EP EP16199741.6A patent/EP3156486A3/en not_active Withdrawn
- 2007-04-13 WO PCT/US2007/066619 patent/WO2007121347A2/en not_active Ceased
- 2007-04-13 MX MX2008013068A patent/MX2008013068A/es active IP Right Grant
- 2007-04-13 US US12/296,621 patent/US8048863B2/en active Active
- 2007-04-13 CN CN2010105249510A patent/CN101972483A/zh active Pending
- 2007-04-13 MX MX2013005786A patent/MX345954B/es unknown
- 2007-04-13 EP EP07760636A patent/EP2004240A4/en not_active Ceased
-
2008
- 2008-10-14 ZA ZA200808744A patent/ZA200808744B/xx unknown
-
2011
- 2011-06-30 US US13/172,964 patent/US8865671B2/en active Active
-
2013
- 2013-07-17 AU AU2013207601A patent/AU2013207601B2/en not_active Ceased
-
2014
- 2014-05-05 US US14/270,174 patent/US9371529B2/en active Active
-
2016
- 2016-05-17 US US15/156,430 patent/US20160257963A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2662446A2 (en) | 2013-11-13 |
| EP3156486A3 (en) | 2017-07-12 |
| US20140357695A1 (en) | 2014-12-04 |
| ZA200808744B (en) | 2009-12-30 |
| JP2009533475A (ja) | 2009-09-17 |
| WO2007121347A2 (en) | 2007-10-25 |
| EP2004240A4 (en) | 2010-12-15 |
| TW201336514A (zh) | 2013-09-16 |
| US8048863B2 (en) | 2011-11-01 |
| US9371529B2 (en) | 2016-06-21 |
| CA2649138A1 (en) | 2007-10-25 |
| KR20080110900A (ko) | 2008-12-19 |
| CA2649138C (en) | 2018-04-03 |
| AU2007238027B2 (en) | 2013-08-15 |
| MX345954B (es) | 2017-02-16 |
| US20090324507A1 (en) | 2009-12-31 |
| BRPI0709506A2 (pt) | 2011-07-19 |
| CN101972483A (zh) | 2011-02-16 |
| AU2007238027A1 (en) | 2007-10-25 |
| EP2662446A3 (en) | 2014-04-02 |
| AU2013207601B2 (en) | 2016-11-17 |
| US20110288157A1 (en) | 2011-11-24 |
| US20160257963A1 (en) | 2016-09-08 |
| CN101443020A (zh) | 2009-05-27 |
| WO2007121347A3 (en) | 2008-12-04 |
| MX2008013068A (es) | 2008-12-16 |
| US8865671B2 (en) | 2014-10-21 |
| EP3156486A2 (en) | 2017-04-19 |
| TW200808360A (en) | 2008-02-16 |
| EP2004240A2 (en) | 2008-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR060448A1 (es) | Inhibicion mediada por rnai de afecciones inflamatorias relacionadas con tirosina quinasa del bazo | |
| ECSP088218A (es) | Bencimidazoles sustituidos como inhibidores de cinasa | |
| CO6351725A2 (es) | Derivados de picolinamida como inhibidores de quinasa | |
| UY32462A (es) | Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644 | |
| BR112012016797A2 (pt) | intensificador dinâmico de baixo utilizando compressor com equalizador incorporado | |
| EA201100427A1 (ru) | Гетероциклические ингибиторы киназы | |
| NI200900106A (es) | Inhibidores de la actividad de la akt. | |
| MX2013011721A (es) | Metodos para tratar condiciones asociadas con la activacion del complemento dependiente de masp-2. | |
| AR061066A1 (es) | Coterapeutica para el tratamiento de epilepsia y trastornos relacionados | |
| CL2011000504A1 (es) | Compuestos derivados de piridin-4-il-tiazol-2il-amida 2-amida-pirrolidin-1,2-dicarboxilico, inhibidores de quinasa de fosfatidil-inositol-3; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de un medicamento para el tratamiento del cancer. | |
| MX2011011854A (es) | Dihidropirimidinonas para uso como inhibidores de la bace2. | |
| ECSP10010559A (es) | Compuestos heterociclicos novedosos y usos de los mismos | |
| BR112012014760A2 (pt) | "composições orgânicas para tratar doenças relacionadas a hsf1, bem como seu uso" | |
| CO6321241A2 (es) | Derivados de 1,3,4- tiadiazol espiro condensados para la inhibicion de la actividad de quinesina (ksp) | |
| CR10166A (es) | Uso de derivados de sulfamida heterociclo benzo-fusionado para el tratamiento del trastorno bipolar y mania | |
| ECSP066882A (es) | Compuestos de imidazol | |
| CL2020002563A1 (es) | Uso de inhibidores de fubp1 para el tratamiento de infección de virus de hepatitis b | |
| BR112014028041A2 (pt) | tratamento de obesidade hipotalâmica com inibidores de metap2 | |
| MX2011011656A (es) | Uso de los inhibidores de la fosfodiesterasa 7 para el tratamiento de trastornos del movimiento. | |
| MX2010005047A (es) | Inhibidores de aldh-2 en el tratamiento de enfermedades psiquiatricas. | |
| CL2008000202A1 (es) | Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor. | |
| UY32312A (es) | 4-azetidinil-1-heteroaril-ciclohexanol antagonistas del ccr2 | |
| WO2007143557A3 (en) | Compounds and methods for treating mammalian gastrointestinal parasitic infections | |
| BR112017016488A2 (pt) | triazóis substituídos e métodos relacionados aos mesmos | |
| AR064016A1 (es) | Inhibicion mediada por arni de acuaporina 4 para tratamiento de afecciones relacionadas con pio |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |